Market Overview

A Peek Into The Market Before The Trading Starts

A Peek Into The Market Before The Trading Starts
Related BBRY
Imperial Capital Warns On BlackBerry, Sees Priv Distribution Challenges
Sprint May Not Sell BlackBerry's Latest Release
BlackBerry Commits To Hardware, And Past Mistakes (Seeking Alpha)
Related MDCO
Earnings Scheduled For February 17, 2016
The Medicines Company Appoints Sarissa Capital Management Exec To Its Board Of Directors
A Prescription For High Risk Fever (Seeking Alpha)

Pre-open movers US stock futures are slightly lower this morning, as investors are awaiting factory-orders data. Futures for the Dow Jones Industrial Average dropped 18 points to 13,911.00 and S&P 500 index futures fell 2.40 points to 1,504.30. Nasdaq 100 futures declined 2.50 points to 2,754.00.

A Peek Into Global Markets European markets were lower today. The STOXX Europe 600 Index fell 0.28%, London's FTSE 100 Index dropped 0.64%, German DAX 30 Index fell 0.43% and French CAC 40 Index declined 0.78%.

Asian markets ended mixed, with Japan's Nikkei Stock Average rising 0.62%, China's Shanghai Composite surging 0.38% and Australia's S&P/ASX 200 Index dropping 0.26%. Hong Kong's Hang Seng Index declined 0.16% and India's Sensex dropped 0.15%.

Broker Recommendation Analysts at Bernstein upgraded BlackBerry (NASDAQ: BBRY) from “market perform” to “outperform.” The target price for BlackBerry has been raised from $12 to $22.

BlackBerry shares gained 0.35% to close at $13.02 on Friday.

Breaking news

  • The Medicines Company (NASDAQ: MDCO) and Alnylam Pharmaceuticals (NASDAQ: ALNY) announced today that they have formed an exclusive global alliance for the development and commercialization of Alnylam's ALN-PCS RNAi therapeutic program for the treatment of hypercholesterolemia. To read the full news, click here.
  • Humana (NYSE: HUM) reported a drop in its fourth-quarter net profit. To read the full news, click here.
  • ICON plc (NASDAQ: ICLR) today announced that it has agreed, subject to certain closing conditions, to acquire the Clinical Trial Services Division of Cross Country Healthcare (NASDAQ: CCRN), for a cash consideration of $52 million, plus an earn-out of up to $3.75 million related to certain performance-based milestones. To read the full news, click here.
  • United Therapeutics (NASDAQ: UTHR) today announced that its Board of Directors authorized the repurchase of up to an additional $420 million of the company's common stock. To read the full news, click here.

Posted-In: Bernstein US Stock FuturesNews Futures Global Pre-Market Outlook Markets


Related Articles (ALNY + BBRY)

View Comments and Join the Discussion!